Clinical Trial Update: Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the combination of regorafenib and durvalumab for high-risk hepatocellular carcinoma is currently active but not recruiting. The tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Regorafenib (regorafenib)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8 | Phase 2 | Status: ACTIVE_NOT_RECRUITING